Risk Migration ( ct2c=high)
|
|
- Jack Park
- 5 years ago
- Views:
Transcription
1 Risk Migration ( ctc=high) Prostate Cancer Over- Detection, but Selective Treatment Active Surveillance Peter R. Carroll, MD, MPH Department of Urology University of California, San Francisco February, 9 Increased Incidence of Very Low Risk Prostate Cancer The Risk of Overdetection Lead Time Bias Rates of Prostate Cancer Detected on Autopsy Decreasing* Increasing Percentage of Men Identified on Screening to Have Very Low Risk Disease Increasing Treatment of Men with Very Low Risk Disease Scheme Single 55 yrs. 4 -Yr (55-67) Annual * Lead Time (yrs) Overdetection (%) 7% 48% 5% J Urol 174: 1785 Lifetime prostate cancer risk increased by 8% (range = 69%- 116%). Extending annual or quadrennial screening to the age of 75 results in at least two cases of overdetection for every clinically relevant cancer detected J Natl Cancer Inst. 3 Jun 18;95(1):
2 Natural History of Screen Detected Cancers Radical Prostatectomy vs. Watchful Waiting Grade < 7 Lead time (years) year CS mortality (%) 1 15 year survival benefit (%) Assumes biennial PSA screening C Parker et al 6 ASCO Prostate Cancer Symposium CaP specific mortality in WW group <65 yrs highest at 19.% Only 5% men diagnosed from screening Significant number of intermediate and high risk disease Bill-Axelson, A. et al. Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer NEJM, 5 Evolution of Watchful Waiting Active Surveillance Old Less well assessed Patients well assessed Usually more advanced Early stage disease Monitoring not rigid/planned Monitored closely Treatment delayed until Treatment at first sign of clinically significant, progression symptomatic disease noted Managed with androgen deprivation New Treated based on risk; local therapy Watchful Waiting Rationale The management of clinically localized prostate cancer is controversial Retrospective epidemiological studies have shown that low grade localized cancer is associated with a limited risk of progression to symptoms or death from cancer Aggressive screening has resulted in detection of early stage lesions of uncertain biologic/clinical potential (stage migration) Ideal treatment/intensive monitoring should be directed to those patients who will progress Paucity of studies examining the variables associated with progression
3 What Predicts for Watchful Waiting? Who Undergoes Watchful Waiting? Age Insurance Status Co - morbidity Cancer risk group Not education, ethnicity or income Surveillance - Trends CaPSURE Active Surveillance How Common in Those Eligible? ELIGIBILITY FOR WW VALUE N (%) PSA <1 AT DX No 5 6 Yes NO GLEASON 4/5 PATTERN AT DX No 8 43 Yes POSITIVE BIOPSY <33% No Yes T1 OR TA AT DX No Yes PSA DENSITY <.15 AT DX No 1 63 Yes MET ALL 5 CRITERIA No Yes Yes No Low Intermediate High PSA < 1; No GS 4/5 and T1/Ta all more common with time. Eligibility predicted by age, insurance status, education and income J Urol. 8 Oct;18(4):
4 Watchful Waiting Hypotheses Surveillance - Results Surveillance in low risk patients is feasible and associated with a low risk of progression Progression can be quantitated Predictors of progression and treatment can be identified Watchful Waiting Cohort UCSF Prostate Cancer Databa Entry Criteria for WW* PSA < 1 Gleason < 6, No GG 4/5 <Tc UCSF Cohort Over 56 men enrolled All men who meet criteria are offered surveillance Mean age is 63 Mean PSA is 6.5 9% Gleason score=6 Patients on Watchful Waiti n = 56 Complete data n = 319 4
5 UCSF Active Surveillance cohort Cohort disease features Entry criteria PSA<1 Gleason sum 6, no pattern 4/5 Stage T1-T 33% cores positive, 5% any single core positive PSA Gleason Cores positive Clinical stage 1ng/ml >1ng/ml <7 7-1 <33% >33% T1 T 6 (87%) 38 (13%) 77 (9%) 4 (8%) 5 (84%) 43 (16%) (64%) 114 (36%) Risk category Low Intermediate High (81%) 7 (15%) 9 (3%) Progression Median f/u 3.6 years Progression defined as: PSA velocity >.75 ng/ml/yr Rise Gleason score Increase lesion size on ultrasound PSA DT? Not validated Type of progression 37% have evidence of progression 38% increase Gleason score 6% high PSAV PSAV does not correlate with Gleason changes US Lesion size data difficult to interpret PSA characteristics PSAV>.75 ng/ml/yr=6% PSAV> ng/ml/yr =15% Median PSADT=6.7 years 5
6 Active Treatment Time to Active Treatment 4% received secondary treatment Median time to treatment: 3 years (range 1-17 years) 71% of treated men had evidence of clinical progression 8% of cohort treated with no evidence of clinical progression Time to Active Treatment Study Comparisons Author Year Median FU (months) Patients % progr. Current study % De Vries (Rotterdam) % Choo/Klotz (Toronto) % Carter (JHU) % Hardie (RMH) % El-Geneidy (OHSU) % Carter (CPDR) % Patel (MSKCC) % 6
7 Predictors of Treatment p value HR 95% CI Can we determine predictors of receiving treatment at baseline and over time for men on active surveillance? Rise Gleason score PSAD>.15 Increase lesion size.1. ns ns ns Grade progression is strongest driver of treatment (HR %CI.-7.7) Results OR 95% CI Can we determine predictors of Gleason score increase for men on active surveillance undergoing serial biopsy? Age (continuous) Age ( ( 63) Interval dx to last biopsy ( years vs. 1 1 year) # biopsies # cores diagnosis # cores re-biopsy #pos cores re-biopsy 1.6*.4* 3.1* * Neg biospy before dx *p<.5 7
8 Radical Prostatectomy after Active Surveillance: Pathologic Outcomes Can we determine the risk of untimely progression while on active surveillance (i.e.miss a window of opportunity)? 46 men Median time to RP is 16.4 months Ta Tb Tc T3a T3b N+ Overall n % Met all inclusion Criteria T T3a T3b n 18 3 % Gleason Grade Change at RP N % Risk of Under - staging and/or Grading Up - grading/staging No change Gleason 7 to 6 Gleason 8 to 7 Gleason 6 to 7 Gleason 7 to 9 Of 9 men with at least 1 surveillance bx, 6 (%) were upgraded after RP vs. 5 of 17 (9%) with no surveillance bx Percent Toronto Royal Marsden Upgrade ECE SVI JHH MSKCC UCSF 3 8
9 Impact of upgrading or staging Active Surveillance Best Candidates Based on Extended - Pattern Biopsy Low grade (no pattern 4 or 5) Low volume (< 33% of core); < 33% of total core Non - palpable (T1C) Serum PSA < 1 ng/ml; Stable, Free - Fraction Elevated, PSAD <.15 Older Age and/or Significant Co - Morbidity Available for Follow - up A well - performed biopsy essential CaP Diagnosis Eligibility PSA <1 Gleason sum <7 (no pattern 4/5) Clinical stage Ta 33% of biopsy cores involved 5% of any single core involved Criteria for study withdrawal PSA doubling < 1 months Evidence of clinical progression Adverse pathological finding (grade progression, 1/3 of cores positive or >5% of any core involved Patient preference THE FUTURE Accession Re-biopsy (extended pattern) mrna microarray analysis Randomization to dietary intervention Serum markers (PSA, %fpsa, T, E, etc) Baseline HRQOL assessment No progression Q3 months: PSA, %fpsa, DRE At 1 months, and q1 months: HRQOL assessment TRUS/biopsy At 3 months Re-biopsy for diagnosis, mrna analysis DRE Serum markers (PSA, %fpsa, T, E, etc) Formal dietary intervention ends Progression Standard treatment per physician, patient preferences 9
10 Effect of Lifestyle Intervention Conclusions The molecular mechanisms by which improvements in diet and lifestyle might affect the prostate microenvironment are poorly understood. A pilot study to examine changes in prostate gene expression Secondary an intensive nutrition and lifestyle intervention. 48 upregulated and 453 downregulated transcripts after the intervention. Pathway analysis identified significant modulation of biological processes that have critical roles in tumorigenesis. Active surveillance appears feasible 4% of men treated a median of 3 years after diagnosis Small percentage of men come off of surveillance despite no evidence of disease progression Overall median f/u remains short Change in Gleason grade is greatest driver of treatment Proc Natl Acad Sci U S A. 8 Jun 17;15(4): Acknowledgements Nannette Perez, RN, NP Kirsten Greene, MD. MS Katsuto Shinohara, MD Janet Cowan Matt Cooperberg, MD, MPH Badri Konety, MD, MBA Max Meng, MD June Chan, PhD Chris Haqq, MD, PhD Dean Ornish, MD - PMRI Vincent Fradet, MD Simon Conti, MD Marc Dallera, MD UCSF Prostate SPORE 1
Prostate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationACTIVE SURVEILLANCE OR WATCHFUL WAITING
Prostate Cancer ACTIVE SURVEILLANCE OR WATCHFUL WAITING María Teresa Bourlon, MD MS Head, Urologic Oncology Clinic Hemato-Oncology Department Instituto Nacional de Ciencias Médicas y Nutrición Salvador
More informationSommerakademie Munich, June
Active surveillance: Shrinking the grey zone Sommerakademie Munich, June 30 2016 Active surveillance Overview of 20 year history Laurence Klotz, MD, CM Professor of Surgery Sunnybrook Heatlh Sciences Centre
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationWhere are we with PSA screening?
Where are we with PSA screening? Faculty/Presenter Disclosure Rela%onships with commercial interests: None Disclosure of Commercial Support This program has received no financial support. This program
More informationPre-test. Prostate Cancer The Good News: Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest
Pre-test Matthew R. Cooperberg, MD, MPH UCSF 40 th Annual Advances in Internal Medicine Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest 1. I do not offer routine PSA screening, and
More informationProstate Cancer Who needs active surveillance?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller Prostate Cancer Who needs active surveillance? Klinische und molekulare Charakterisierung des Hoch-Risiko-Prostatakarzinoms.
More informationACTIVE SURVEILLANCE FOR PROSTATE CANCER
ACTIVE SURVEILLANCE FOR PROSTATE CANCER Dr. Michael J Metcalfe PGY-2 Department of Urological Sciences April 25, 2012 CASE RM 65 year old active Caucasian male, married. PSA= 7.0 T2a Gleason 3+3=6 2/6
More informationProstate Cancer Screening: Risks and Benefits across the Ages
Prostate Cancer Screening: Risks and Benefits across the Ages 7 th Annual Symposium on Men s Health Continuing Progress: New Gains, New Challenges June 10, 2009 Michael J. Barry, MD General Medicine Unit
More informationBPH with persistently elevated PSA 아주대학교김선일
BPH with persistently elevated PSA 아주대학교김선일 PSA in BPH: present status AUA & EAU BPH guideline: PSA: recommended test AUA practice guideline committee. J Urol 2003;170:530 Madersbacher. Eur Urol 2004;46:547
More informationPROSTATE CANCER SURVEILLANCE
PROSTATE CANCER SURVEILLANCE ESMO Preceptorship on Prostate Cancer Singapore, 15-16 November 2017 Rosa Nadal National Cancer Institute, NIH Bethesda, USA DISCLOSURE No conflicts of interest to declare
More informationConceptual basis for active surveillance
Conceptual basis for active surveillance 1. Screening results in overdiagnosis 2. Clinically insignificant disease can be identified 3. All treatments have significant side effects and cost. 4. Delayed
More informationJ Clin Oncol 29: by American Society of Clinical Oncology INTRODUCTION
VOLUME NUMBER 20 JULY 10 2011 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Changes in Prostate Cancer Grade on Serial Biopsy in Men Undergoing Active Surveillance Sima P. Porten, Jared M. Whitson,
More informationAdam Raben M.D. Helen F Graham Cancer Center
Adam Raben M.D. Helen F Graham Cancer Center Is the biopsy sample representative of the extent of the disease in your patient with clinically low-risk prostate cancer? BIOPSY RP registry (n=8095) 3+3=6
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationActive surveillance: Shrinking the grey zone. Sommerakademi e Munich, June rd FOIUS Tel Aviv, July 2016
Active surveillance: Shrinking the grey zone Active surveillance: 3 rd FOIUS Tel Aviv, July 2016 Shrinking the grey zone Sommerakademi e Munich, June 30 2016 Active Surveillance for low risk PCa What has
More informationEarly outcomes of active surveillance for localized prostate cancer
Original Article ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER HARDIE et al. Early outcomes of active surveillance for localized prostate cancer CLAIRE HARDIE, CHRIS PARKER, ANDREW NORMAN*, ROS EELES,
More informationPSA testing in New Zealand general practice
PSA testing in New Zealand general practice Ross Lawrenson, Charis Brown, Fraser Hodgson. On behalf of the Midland Prostate Cancer Study Group Academic Steering Goup: Zuzana Obertova, Helen Conaglen, John
More informationHow will new biomarkers change prostate cancer management
How will new biomarkers change prostate cancer management Matthew R. Cooperberg, MD, MPH Departments of Urology and Epidemiology & Biostatistics BAUS Section of Oncology Annual Meeting Cardiff, UK 15 November
More informationProstate Cancer Incidence
Prostate Cancer: Prevention, Screening and Treatment Philip Kantoff MD Dana-Farber Cancer Institute Professor of fmedicine i Harvard Medical School Prostate Cancer Incidence # of patients 350,000 New Cases
More informationActive Surveillance for Intermediate Risk Prostate Cancer
Active Surveillance for Intermediate Risk Prostate Cancer Eric Wallen, M.D., FACS Professor Department of Urology The University of North Carolina at Chapel Hill Disclosures: None Objectives Understand
More informationUntreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes
Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes A. A. Hussein,* C. J. Welty,* N. Ameli,* J. E. Cowan, M. Leapman,*
More information2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment
Why Discuss this topic? Mack Roach III, MD Professor and Chair Radiation Oncology UCSF Managing Local Recurrences after Radiation Failure 1. ~15 to 75% of CaP pts recur after definitive RT. 2. Heterogeneous
More informationProstate Cancer. Axiom. Overdetection Is A Small Issue. Reducing Morbidity and Mortality
Overdetection Is A Small Issue (in the context of decreasing prostate cancer mortality rates and with appropriate, effective, and high-quality treatment) Prostate Cancer Arises silently Dwells in a curable
More informationProstate Cancer Active Surveillance: Rationale, Outcomes and Future Directions
Prostate Cancer Active Surveillance: Rationale, Outcomes and Future Directions Daniel W. Lin, MD Professor and Chief of Urologic Oncology Bridges Endowed Professorship of Prostate Cancer Research Department
More informationUnderstanding the Performance of Active Surveillance Selection Criteria in Diverse Urology Practices
Understanding the Performance of Active Surveillance Selection Criteria in Diverse Urology Practices Scott R. Hawken,* Paul R. Womble,* Lindsey A. Herrel, Zaojun Ye, Susan M. Linsell, Patrick M. Hurley,
More informationNewer Aspects of Prostate Cancer Underwriting
Newer Aspects of Prostate Cancer Underwriting Presented By: Jack Swanson, M.D. Keith Hoffman, NFP Moments Made Possible Objectives To review and discuss Conflicting messages about PSA testing Cautions
More informationSorveglianza Attiva update
Sorveglianza Attiva update Dr. Sergio Villa Dr. Riccardo Valdagni www.thelancet.com Published online August 7, 2014 http://dx.doi.org/10.1016/s0140-6736(14)60525-0 the main weakness of screening is a high
More informationPCa Commentary. Executive Summary: The "PCa risk increased directly with increasing phi values."
1101 Madison Street Suite 1101 Seattle, WA 98104 P 206-215-2490 www.seattleprostate.com PCa Commentary Volume 77 September October 2012 CONTENT Page The Prostate 1 Health Index Active Surveillance 2 A
More informationEstimating and comparing cancer progression risks under varying surveillance protocols: moving beyond the Tower of Babel
Estimating and comparing cancer progression risks under varying surveillance protocols: moving beyond the Tower of Babel Jane Lange March 22, 2017 1 Acknowledgements Many thanks to the multiple project
More informationProstate Biopsy. Prostate Biopsy. We canʼt go backwards: Screening has helped!
We canʼt go backwards: Screening has helped! Robert E. Donohue M.D. Denver V.A. Medical Center University of Colorado Prostate Biopsy Is cure necessary; when it is possible? Is cure possible; when it is
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationProstate Cancer: Screening, Treatment, and Survivorship
Prostate Cancer: Screening, Treatment, and Survivorship Timothy C. Brand, MD, FACS LTC(P), MC, USA Urology Residency Director Associate Professor of Surgery, USUHS Madigan Army Medical Center No Disclosures
More informationProstate MRI: Who needs it?
Prostate MRI: Who needs it? Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Abdominal Imaging Magnetic Resonance Science Center
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationRadical Prostatectomy:
Overtreatment and undertreatment Radical Prostatectomy: An Emerging Standard of Care for High Risk Prostate Cancer Matthew R. Cooperberg, MD,MPH UCSF Radiation Oncology Update San Francisco, CA April 2,
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationMr Declan Cahill Consultant Urological Surgeon The Royal Marsden
Diagnosing prostate cancer Mr Declan Cahill Consultant Urological Surgeon 2 Marsden GP Education Day 22 February 2016 Should I have a PSA test? Can I have a PSA test? prostatecanceruk.org 4 83% raised
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationLocalized prostate cancer
Prostate Cancer 2014 Localized prostate cancer Progress toward personalized care Matthew R. Cooperberg, MD,MPH Departments of Urology and Epidemiology & Biostatistics UCSF Mini Medical School July 22,
More informationUrological Society of Australia and New Zealand PSA Testing Policy 2009
Executive summary Urological Society of Australia and New Zealand PSA Testing Policy 2009 1. Prostate cancer is a major health problem and is the second leading cause of male cancer deaths in Australia
More informationFactors Associated with Initial Treatment for Clinically Localized Prostate Cancer
Factors Associated with Initial Treatment for Clinically Localized Prostate Cancer Preliminary Results from the National Program of Cancer Registries Patterns of Care Study (PoC1) NAACCR Annual Meeting
More informationTo be covered. Screening, early diagnosis, and treatment including Active Surveillance for prostate cancer: where is Europe heading for?
To be covered Screening, early diagnosis, and treatment including Active Surveillance for prostate cancer: where is Europe heading for? Europa Uomo meeting Stockholm 29 Chris H.Bangma Rotterdam, The Netherlands
More informationThe Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon
Prostate case study Presented by Mr Alan Thompson Consultant Urological Surgeon 2 Part one Initial presentation A 62 year old male solicitor attends your GP surgery. He has rarely seen you over the last
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationHealth Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015
Health Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015 Outline Epidemiology of prostate cancer Purpose of screening Method of screening Contemporary screening trials
More informationExpanded criteria for active surveillance in prostate cancer: a review of the current data
Review Article Expanded criteria for active surveillance in prostate cancer: a review of the current data Cameron Jones 1, Mina M. Fam 2, Benjamin J. Davies 2 1 University of Pittsburgh School of Medicine,
More informationUCSF UC San Francisco Previously Published Works
UCSF UC San Francisco Previously Published Works Title Patterns of practice in the United States: insights from CaPSURE on prostate cancer management. Permalink https://escholarship.org/uc/item/24j7405c
More informationMR-US Fusion Guided Biopsy: Is it fulfilling expectations?
MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology
More informationLocal Recommendations for Active Surveillance of Prostate Cancer
February 15 Local Recommendations for Active Surveillance of Prostate Cancer Chris Dawson Urology Lead Clinician February 2015 www.pchurology.co.uk Summary and Recommendations 1. There is no single set
More informationClinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline Very Low-/Low-Risk Disease
Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline Very Low-/Low-Risk Disease Jeffrey A. Cadeddu, MD Professor, Department of Urology UT Southwestern Medical Center Vice-Chair, AUA/ASTRO/SUO
More informationPaul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia
Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia Virginia - Chesapeake Bay Landfall: Virginia Beach, April 29 th, 1607 PSA Failure after Radical Prostatectomy
More informationContemporary Approaches to Screening for Prostate Cancer
Contemporary Approaches to Screening for Prostate Cancer Gerald L. Andriole, MD Robert K. Royce Distinguished Professor Chief of Urologic Surgery Siteman Cancer Center Washington University School of Medicine
More informationJ Clin Oncol by American Society of Clinical Oncology INTRODUCTION
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Active Surveillance in Younger Men With Prostate Cancer Michael S. Leapman, Janet E. Cowan, Hao G. Nguyen, Katsuto K. Shinohara, Nannette Perez,
More informationMRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know
MRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know Michael S. Cookson, MD, FACS Professor and Chair Department of Urology Director of Prostate and Urologic Oncology University
More informationMichigan Urological Surgery Improvement Collaborative
Michigan Urological Surgery Improvement Collaborative Making Michigan #1 in Prostate Cancer Care Jim Montie, MD Susan Linsell, MHSA February 10, 2015 Vital statistics MUSIC Participants: 42 practices 235
More informationProstate Cancer Screening. Eric Shreve, MD Bend Urology Associates
Prostate Cancer Screening Eric Shreve, MD Bend Urology Associates University of Cincinnati Medical Center University of Iowa Hospitals and Clinics PSA Human kallikrein 3 Semenogelin is substrate Concentration
More informationActive Surveillance with High Resolution Color-Doppler Transrectal Ultrasound Monitoring: Is it fool-proof?
Active Surveillance with High Resolution Color-Doppler Transrectal Ultrasound Monitoring: Is it fool-proof? Duke Bahn MD Prostate Institute of America, Ventura, California INTRODUCTION In the November
More informationClinical Case Conference
Clinical Case Conference Intermediate-risk prostate cancer 08/06/2014 Long Pham Clinical Case 64 yo man was found to have elevated PSA of 8.65. TRUS-biopies were negative. Surveillance PSA was 7.2 in 3
More informationPublished Ahead of Print on April 4, 2011 as /JCO J Clin Oncol by American Society of Clinical Oncology INTRODUCTION
Published Ahead of Print on April 4, 2011 as 10.1200/JCO.2010.32.8112 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2010.32.8112 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E
More informationProstate Cancer Genomics When To Treat and With What? Ashley E. Ross, M.D., Ph.D. Texas Urology Specialists August 2017
Prostate Cancer Genomics When To Treat and With What? Ashley E. Ross, M.D., Ph.D. Texas Urology Specialists August 2017 Relevant Disclosures Advisory role, ownership interest, previous unrestricted grant
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #104 (NQF 0390): Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS
More informationProstate Cancer Innovations in Surgical Strategies Update 2007!
Prostate Cancer Innovations in Surgical Strategies Update 2007! Curtis A. Pettaway, M.D. Professor Department of Urology The University of Texas M. D. Anderson Cancer Center Radical Prostatectomy Pathologic
More informationDebate: Whole pelvic RT for high risk prostate cancer??
Debate: Whole pelvic RT for high risk prostate cancer?? WPRT well, at least it ll get the job done.or will it? Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Using T-stage,
More informationLong-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer
Published Ahead of Print on December 15, 1 as 1.1/JCO.1.55.119 The latest version is at http://jco.ascopubs.org/cgi/doi/1.1/jco.1.55.119 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Long-Term
More informationEarly Experience With Active Surveillance in Low-Risk Prostate Cancer Treated
www.kjurology.org http://dx.doi.org/.4/kju.4...67 Original Article Urological Oncology http://crossmark.crossref.org/dialog/?doi=.4/kju.4...67&domain=pdf&date_stamp=47 Early Experience With Active Surveillance
More informationPSA and the Future. Axel Heidenreich, Department of Urology
PSA and the Future Axel Heidenreich, Department of Urology PSA and Prostate Cancer EAU Guideline 2011 PSA is a continuous variable PSA value (ng/ml) risk of PCa, % 0 0.5 6.6 0.6 1 10.1 1.1 2 17.0 2.1 3
More informationHow to detect and investigate Prostate Cancer before TRT
How to detect and investigate Prostate Cancer before TRT Frans M.J. Debruyne Professor of Urology Andros Men s Health Institutes, The Netherlands Bruges, 25-26 September 2014 PRISM Recommendations for
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationHow do I control (monitor) patients receiving TRT after prostate cancer treatment
How do I control (monitor) patients receiving TRT after prostate cancer treatment Anthony J. Bella MD, FRCSC Greta and John Hansen Chair in Men s Health Research Division of Urology, Department of Surgery
More informationTiming of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model
Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted
More informationPSA Screening and Prostate Cancer. Rishi Modh, MD
PSA Screening and Prostate Cancer Rishi Modh, MD ABOUT ME From Tampa Bay Went to Berkeley Prep University of Miami for Undergraduate - 4 years University of Miami for Medical School - 4 Years University
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationPROSTATE CANCER Amit Gupta MD MPH
PROSTATE CANCER Amit Gupta MD MPH Depts. of Urology and Epidemiology Amit-Gupta-1@uiowa.edu dramitgupta@gmail.com Tel: 319-384-5251 OUTLINE PSA screening controversy How to use PSA more effectively Treatment
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationPREDICTION OF PROSTATE CANCER PROGRESSION
EVALUATION OF PROSTAE SPECIFIC ANTIGEN (PSA) KINETICS IN PREDICTION OF PROSTATE CANCER PROGRESSION by Dongyu Zhang A thesis submitted to Johns Hopkins University in conformity with the requirements for
More informationMolDX: Oncotype DX Genomic Prostate Score for Men with Favorable Intermediate Risk Prostate Cancer
MolDX: Oncotype DX Genomic Prostate Score for Men with Favorable Intermediate Risk Prostate Cancer Noridian Healthcare Solutions, LLC Please Note: This is a Proposed LCD. Proposed LCDs are works in progress
More information3/22/2014. Goals of this Presentation: in 15 min & 5 min Q & A. Radiotherapy for. Localized Prostate Cancer: What is New in 2014?
3/22/ Goals of this Presentation: in 15 min & 5 min Q & A 1. Potency Preservation. a. Dosimetric considerations Radiotherapy for b. Drugs 2. Update on duration of short term ADT Mack III, MD Professor
More informationPSA Doubling Time Versus PSA Velocity to Predict High-Risk Prostate Cancer: Data from the Baltimore Longitudinal Study of Aging
european urology 54 (2008) 1073 1080 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer PSA Doubling Time Versus PSA Velocity to Predict High-Risk Prostate Cancer:
More informationFOR PATIENTS DIAGNOSED WITH EARLY-STAGE PROSTATE CANCER. Discover a test that can help you on your treatment journey
FOR PATIENTS DIAGNOSED WITH EARLY-STAGE PROSTATE CANCER Discover a test that can help you on your treatment journey Jim G. Oncotype DX GPS patient navigating prostate cancer since 2014 Not all prostate
More informationProstate MRI for local staging and surgical planning in prostate cancer
Prostate MRI for local staging and surgical planning in prostate cancer 15th Annual Floyd A. Fried Advances in Urology Symposium June 23, 2017 Ray Tan, MD, MSHPM Assistant Professor Disclosures None Objectives
More informationTrends in Prostate Cancer Bob Weir AVP Underwriting Research Canada Life Reinsurance
Trends in Prostate Cancer Bob Weir AVP Underwriting Research Canada Life Reinsurance Metropolitan Underwriting Discussion Group Annual Meeting January 30, 2017 Prostate Cancer is Common Rudy Giuliani Dx
More informationLow risk. Objectives. Case-based question 1. Evidence-based utilization of imaging in prostate cancer
Evidence-based utilization of imaging in prostate cancer Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Objectives State the modalities,
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationCurrent Clinical Practice. MR Imaging Evaluations. MRI Anatomic Review. Imaging to Address Clinical Challenges. Prostate MR
BETH ISRAEL DEACONESS MEDICAL CENTER Prostate MR Neil M. Rofsky, MD Harvard Medical School Current Clinical Practice DIGITAL RECTAL EXAMINATION PSA ( ~ 20% False negative) BIOPSY (18-25% False negative)
More informationPredictive Models. Michael W. Kattan, Ph.D. Department of Quantitative Health Sciences and Glickman Urologic and Kidney Institute
Predictive Models Michael W. Kattan, Ph.D. Department of Quantitative Health Sciences and Glickman Urologic and Kidney Institute Treatment for clinically localized prostate cancer Trade off: Substantial
More informationAppreciating the Natural History of Prostate Cancer in 2005: The Art of Medicine
Appreciating the Natural History of Prostate Cancer in 2: The Art of Medicine Larry Goldenberg, MD, FRCSC, FACS The Prostate Centre at VGH, University of British Columbia, Vancouver, Canada Prostate Cancer:
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More informationIntroduction. American Society of Clinical Oncology All rights reserved.
Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement This is an endorsement
More informationThe accuracy of prostate biopsy to assign patients with low-grade prostate cancer to active surveillance
Boston University OpenBU Theses & Dissertations http://open.bu.edu Boston University Theses & Dissertations 2014 The accuracy of prostate biopsy to assign patients with low-grade prostate cancer to active
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationMonique J. Roobol. Active Surveillance: update on Initiatives
Monique J. Roobol Associate professor Dept. of Urology Erasmus University Medical Center Rotterdam, the Netherlands Active Surveillance: update on Initiatives Overview Studies on Active Surveillance world
More informationActive Surveillance for Prostate Cancer: A Systematic Review of the Literature
EUROPEAN UROLOGY 62 (2012) 976 983 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Collaborative Review Prostate Cancer Editorial by Gurdarshan S. Sandhu
More informationconcordance indices were calculated for the entire model and subsequently for each risk group.
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai
More informationPROSTATE CANCER IN JAMAICA
PROSTATE CANCER IN JAMAICA LOCAL PROFILE OF PROSTATE CANCER - A review of TRUS biopsy data DR MARIE BROWN (ELECTIVE RESIDENT) 1 OBJECTIVES Background on Jamaica/ Jamaicans Review the incidence and mortality
More informationProstate Cancer. 3DCRT vs IMRT : Hasan Murshed
Prostate Cancer 3DCRT vs IMRT : the second debate Hasan Murshed Take home message IMRT allows dose escalation. Preliminary data shows IMRT technique improves cancer control while keeping acceptable morbidity
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer
More informationPredicting the Probability of Deferred Radical Treatment for Localised Prostate Cancer Managed by Active Surveillance
european urology 54 (2008) 1297 1305 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Predicting the Probability of Deferred Radical Treatment for Localised
More information